Nuvation Bio Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Nuvation Bio reported Q3 2026 revenue of $45.0M ($27.5M from IBTROZI product sales, up 18% QoQ; $17.5M from collaborations). IBTROZI established as #1 prescribed ROS1 TKI by IQVIA data, with ~160 new patient starts in Q3 (65% TKI-naïve). FDA approved sNDA showing 49.7-month median duration of response in TRUST-I. Safusidenib received FDA Fast Track Designation for IDH1-mutant glioma. Cash position: $663.4M (including $36.5M from July 2026 convertible notes overallotment). Net loss Q3: $41.9M ($0.12/share), improved from $55.8M ($0.16/share) in Q3 2025.
Why this rating
Commercial validation of IBTROZI + regulatory progress on pipeline are meaningful for ~$500M biotech. Near-term revenue trajectory and market share gains offset by ongoing clinical-stage losses and execution risk.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.